Management of Treatment-Resistant Depression in Real -World Clinical Practice Settings Across Asia
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Neuropsychiatric Disease and Treatment
- Vol. 16, 2943-2959
- https://doi.org/10.2147/NDT.S264813
Abstract
Purpose: Consensus is lacking on the management of treatment-resistant depression (TRD), resulting in significant variations on how TRD patients are being managed in real-world practice. A survey explored how clinicians managed TRD across Asia, followed by an expert panel that interpreted the survey results and provided recommendations on how TRD could be managed in real-world clinical settings. Methods: Between March and July 2018, 246 clinicians from Hong Kong, Japan, Mainland China, South Korea, and Taiwan completed a survey related to their treatment approaches for TRD. Results: The survey showed physicians using more polytherapy (71%) compared to maintaining patients on monotherapy (29%). The most commonly (23%) administered polytherapy involved antidepressant augmentation with antipsychotics that 19% of physicians also indicated as their most important approach for managing TRD. The highest number of physicians (34%) ranked switching to another class of antidepressants as their most important approach, while 16% and 9% chose antidepressant combinations and electroconvulsive therapy (ECT), respectively. Conclusion: Taking into account the survey results, the expert panel made general recommendations on the management of TRD. TRD partial-responders to antidepressants should be considered for augmentation with second-generation antipsychotics. For non-responders, switching to another class of antidepressants ought to be considered. TRD patients achieving remission with acute treatment should consider continuing their antidepressants for at least another 6 months to prevent relapse. ECT is a treatment consideration for patients with severe depression or persistent symptoms despite multiple adequate trials of antidepressants. Physicians should also consider the response, tolerability and adherence to the current and previous antidepressants, the severity of symptoms, comorbidities, concomitant medications, preferences, and cost when choosing a TRD treatment approach for each individual patient.This publication has 70 references indexed in Scilit:
- Depression-Related Work Disability: Socioeconomic Inequalities in Onset, Duration and RecurrencePLOS ONE, 2013
- Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims DatabasePLOS ONE, 2013
- World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disordersThe World Journal of Biological Psychiatry, 2013
- Contemporary use and practice of electroconvulsive therapy worldwideBrain and Behavior, 2012
- Treating Depression After Initial Treatment FailureJournal of Clinical Psychopharmacology, 2012
- To use or not to use: an update on licit and illicit ketamine useSubstance Abuse and Rehabilitation, 2011
- If at First You Donʼt SucceedDrugs, 2011
- Meta-Analysis of Relapse Prevention Antidepressant Trials in Depressive DisordersAustralian & New Zealand Journal of Psychiatry, 2010
- A Survey of the Practice of Electroconvulsive Therapy in AsiaThe Journal of ECT, 2010
- Quantitative review of the efficacy of slow-frequency magnetic brain stimulation in major depressive disorderPsychological Medicine, 2010